Microbiologics Acquires Phthisis Diagnostics, New Direction Exhibited at Current Meeting of the Association for Molecular Pathology
|
By LabMedica International staff writers Posted on 11 Nov 2013 |
Phthisis Diagnostics (Charlottesville, VA, USA) has announced its acquisition by Microbiologics (St. Cloud, MN, USA) to establish Phthisis’ technology as the foundation for a new division at Microbiologics.
Pthisis’ patented “G-Sphere” molecular standards product line will be the foundation for Microbiologics’ launch into molecular products and for the new division it is forming. G-Sphere standards are synthetic genes that provide easy-to-use, safe, stable, consistent, and abundant controls for virtually any organism or molecular assay. Currently, Microbiologics produces an array of lyophilized microorganism products in convenient, ready-to-use formats for quality control of microbiological testing.
Crystal Icenhour, PhD, adjunct assistant professor of infectious diseases at Duke University Medical Center, and President and Chief Science Officer at Phthisis since 2006, along with her research team, created the new technology. She will serve as an advisor with Microbiologics during the adoption of Phthisis’ technology and development of their new division. “We introduced this product line about a year ago to provide much needed quality control standards to molecular laboratories. I am pleased that this longer established company will have the structure to take these products much further than our smaller company could have,” said Prof. Icenhour.
Brad Goskowicz, Microbiologics CEO, commented, “These innovative molecular standards will lay the foundation for Microbiologics to design and launch a broad collection of molecular products and custom services. It will expand our range of biomaterials to include viruses and other hard to grow microorganisms.”
Microbiologics is adding Brian Beck, PhD in bacteriology, to its senior management team as Vice President of Molecular Products and Services. Dr. Beck has spent the last ten years at ATCC in Virginia where he managed the Microbiology Collection and Associated BioServices. “I’m quite excited to extend what Microbiologics has done with their culture business and bring that same practical, user-friendly format to the molecular diagnostic business,” said Dr. Beck.
To commence their new initiative, Microbiologics is exhibiting at the Association for Molecular Pathology (AMP) annual meeting, November 14-16, 2013, Phoenix (Arizona, USA).
Related Links:
Phthisis Diagnostics
Microbiologics
Pthisis’ patented “G-Sphere” molecular standards product line will be the foundation for Microbiologics’ launch into molecular products and for the new division it is forming. G-Sphere standards are synthetic genes that provide easy-to-use, safe, stable, consistent, and abundant controls for virtually any organism or molecular assay. Currently, Microbiologics produces an array of lyophilized microorganism products in convenient, ready-to-use formats for quality control of microbiological testing.
Crystal Icenhour, PhD, adjunct assistant professor of infectious diseases at Duke University Medical Center, and President and Chief Science Officer at Phthisis since 2006, along with her research team, created the new technology. She will serve as an advisor with Microbiologics during the adoption of Phthisis’ technology and development of their new division. “We introduced this product line about a year ago to provide much needed quality control standards to molecular laboratories. I am pleased that this longer established company will have the structure to take these products much further than our smaller company could have,” said Prof. Icenhour.
Brad Goskowicz, Microbiologics CEO, commented, “These innovative molecular standards will lay the foundation for Microbiologics to design and launch a broad collection of molecular products and custom services. It will expand our range of biomaterials to include viruses and other hard to grow microorganisms.”
Microbiologics is adding Brian Beck, PhD in bacteriology, to its senior management team as Vice President of Molecular Products and Services. Dr. Beck has spent the last ten years at ATCC in Virginia where he managed the Microbiology Collection and Associated BioServices. “I’m quite excited to extend what Microbiologics has done with their culture business and bring that same practical, user-friendly format to the molecular diagnostic business,” said Dr. Beck.
To commence their new initiative, Microbiologics is exhibiting at the Association for Molecular Pathology (AMP) annual meeting, November 14-16, 2013, Phoenix (Arizona, USA).
Related Links:
Phthisis Diagnostics
Microbiologics
Latest Industry News
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
- Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more







 Analyzer.jpg)
